Skip to main content
NASDAQ:ALLK

Allakos Competitors

$100.54
-0.10 (-0.10 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$97.23
$101.76
50-Day Range
$94.95
$115.14
52-Week Range
$62.34
$157.98
Volume117,366 shs
Average Volume248,004 shs
Market Capitalization$5.39 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.02

Competitors

Allakos (NASDAQ:ALLK) Vs. HZNP, CTLT, ELAN, ALNY, ZLAB, and BMRN

Should you be buying ALLK stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Allakos, including Horizon Therapeutics Public (HZNP), Catalent (CTLT), Elanco Animal Health (ELAN), Alnylam Pharmaceuticals (ALNY), Zai Lab (ZLAB), and BioMarin Pharmaceutical (BMRN).

Allakos (NASDAQ:ALLK) and Horizon Therapeutics Public (NASDAQ:HZNP) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Earnings and Valuation

This table compares Allakos and Horizon Therapeutics Public's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AllakosN/AN/A$-85,370,000.00($1.89)-53.20
Horizon Therapeutics Public$1.30 billion16.22$573.02 million$1.9448.35

Horizon Therapeutics Public has higher revenue and earnings than Allakos. Allakos is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

65.4% of Allakos shares are owned by institutional investors. Comparatively, 88.6% of Horizon Therapeutics Public shares are owned by institutional investors. 44.8% of Allakos shares are owned by insiders. Comparatively, 4.3% of Horizon Therapeutics Public shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Allakos has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Horizon Therapeutics Public has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.

Profitability

This table compares Allakos and Horizon Therapeutics Public's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AllakosN/A-29.18%-27.70%
Horizon Therapeutics Public43.55%25.66%14.19%

Analyst Ratings

This is a breakdown of current ratings and price targets for Allakos and Horizon Therapeutics Public, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allakos00403.00
Horizon Therapeutics Public001103.00

Allakos presently has a consensus price target of $181.50, suggesting a potential upside of 80.53%. Horizon Therapeutics Public has a consensus price target of $111.3636, suggesting a potential upside of 18.74%. Given Allakos' higher possible upside, analysts clearly believe Allakos is more favorable than Horizon Therapeutics Public.

Summary

Horizon Therapeutics Public beats Allakos on 10 of the 12 factors compared between the two stocks.

Catalent (NYSE:CTLT) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Catalent and Allakos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalent9.25%14.20%4.83%
AllakosN/A-29.18%-27.70%

Institutional & Insider Ownership

97.8% of Catalent shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 1.0% of Catalent shares are held by company insiders. Comparatively, 44.8% of Allakos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Catalent and Allakos' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalent$3.09 billion5.62$173 million$1.8854.27
AllakosN/AN/A$-85,370,000.00($1.89)-53.20

Catalent has higher revenue and earnings than Allakos. Allakos is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Catalent has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Allakos has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Catalent and Allakos, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalent01702.88
Allakos00403.00

Catalent currently has a consensus target price of $125.1250, suggesting a potential upside of 22.65%. Allakos has a consensus target price of $181.50, suggesting a potential upside of 80.53%. Given Allakos' stronger consensus rating and higher possible upside, analysts plainly believe Allakos is more favorable than Catalent.

Summary

Catalent beats Allakos on 10 of the 13 factors compared between the two stocks.

Elanco Animal Health (NYSE:ELAN) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Elanco Animal Health and Allakos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Elanco Animal Health-8.45%3.43%2.04%
AllakosN/A-29.18%-27.70%

Institutional & Insider Ownership

86.8% of Elanco Animal Health shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 0.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 44.8% of Allakos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Elanco Animal Health and Allakos' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elanco Animal Health$3.07 billion5.39$67.90 million$1.0633.03
AllakosN/AN/A$-85,370,000.00($1.89)-53.20

Elanco Animal Health has higher revenue and earnings than Allakos. Allakos is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Elanco Animal Health has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Allakos has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Elanco Animal Health and Allakos, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Elanco Animal Health13902.62
Allakos00403.00

Elanco Animal Health currently has a consensus target price of $33.1364, suggesting a potential downside of 5.35%. Allakos has a consensus target price of $181.50, suggesting a potential upside of 80.53%. Given Allakos' stronger consensus rating and higher possible upside, analysts plainly believe Allakos is more favorable than Elanco Animal Health.

Summary

Elanco Animal Health beats Allakos on 7 of the 13 factors compared between the two stocks.

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Alnylam Pharmaceuticals and Allakos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alnylam Pharmaceuticals-222.19%-65.96%-31.38%
AllakosN/A-29.18%-27.70%

Institutional & Insider Ownership

92.4% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 3.5% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 44.8% of Allakos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Alnylam Pharmaceuticals and Allakos' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$219.75 million72.69$-886,120,000.00($8.11)-16.76
AllakosN/AN/A$-85,370,000.00($1.89)-53.20

Allakos has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Allakos is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Alnylam Pharmaceuticals has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Allakos has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Alnylam Pharmaceuticals and Allakos, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alnylam Pharmaceuticals08802.50
Allakos00403.00

Alnylam Pharmaceuticals currently has a consensus target price of $168.7333, suggesting a potential upside of 24.17%. Allakos has a consensus target price of $181.50, suggesting a potential upside of 80.53%. Given Allakos' stronger consensus rating and higher possible upside, analysts plainly believe Allakos is more favorable than Alnylam Pharmaceuticals.

Summary

Allakos beats Alnylam Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Zai Lab (NASDAQ:ZLAB) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Zai Lab and Allakos, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zai Lab00503.00
Allakos00403.00

Zai Lab currently has a consensus target price of $197.8460, suggesting a potential upside of 28.48%. Allakos has a consensus target price of $181.50, suggesting a potential upside of 80.53%. Given Allakos' higher possible upside, analysts plainly believe Allakos is more favorable than Zai Lab.

Profitability

This table compares Zai Lab and Allakos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zai LabN/AN/AN/A
AllakosN/A-29.18%-27.70%

Volatility and Risk

Zai Lab has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Allakos has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Valuation & Earnings

This table compares Zai Lab and Allakos' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zai Lab$12.98 million1,123.31$-195,070,000.00($3.03)-50.82
AllakosN/AN/A$-85,370,000.00($1.89)-53.20

Allakos has lower revenue, but higher earnings than Zai Lab. Allakos is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

81.3% of Zai Lab shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 44.8% of Allakos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Allakos beats Zai Lab on 6 of the 11 factors compared between the two stocks.

Allakos (NASDAQ:ALLK) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for Allakos and BioMarin Pharmaceutical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allakos00403.00
BioMarin Pharmaceutical071002.59

Allakos currently has a consensus target price of $181.50, suggesting a potential upside of 80.53%. BioMarin Pharmaceutical has a consensus target price of $118.20, suggesting a potential upside of 52.83%. Given Allakos' stronger consensus rating and higher possible upside, research analysts plainly believe Allakos is more favorable than BioMarin Pharmaceutical.

Profitability

This table compares Allakos and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AllakosN/A-29.18%-27.70%
BioMarin Pharmaceutical45.74%4.34%2.84%

Risk & Volatility

Allakos has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Earnings and Valuation

This table compares Allakos and BioMarin Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AllakosN/AN/A$-85,370,000.00($1.89)-53.20
BioMarin Pharmaceutical$1.70 billion8.29$-23,850,000.00$0.071,104.86

BioMarin Pharmaceutical has higher revenue and earnings than Allakos. Allakos is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

65.4% of Allakos shares are held by institutional investors. Comparatively, 97.7% of BioMarin Pharmaceutical shares are held by institutional investors. 44.8% of Allakos shares are held by insiders. Comparatively, 2.2% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

BioMarin Pharmaceutical beats Allakos on 9 of the 13 factors compared between the two stocks.


Allakos Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$93.79-1.8%$21.08 billion$1.30 billion25.63Insider Selling
Catalent logo
CTLT
Catalent
1.7$102.02-0.7%$17.38 billion$3.09 billion64.98Analyst Revision
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.9$35.01-0.6%$16.56 billion$3.07 billion-61.42Analyst Report
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$135.89-0.1%$15.97 billion$219.75 million-17.36Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.6$153.99-0.7%$14.58 billion$12.98 million-50.82Earnings Announcement
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$77.34-0.5%$14.13 billion$1.70 billion17.70
Grifols logo
GRFS
Grifols
1.3$18.69-0.3%$12.85 billion$5.71 billion16.69Analyst Upgrade
News Coverage
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$72.00-0.0%$11.97 billion$2.32 billion59.50Earnings Announcement
Analyst Report
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$10.76-1.8%$11.75 billion$16.89 billion-2.92
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$29.25-0.6%$10.48 billion$8.60 billion-5.37
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$176.80-1.3%$10.06 billion$2.16 billion55.77Analyst Report
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.5$38.40-1.2%$9.89 billionN/A0.00Earnings Announcement
Analyst Report
Lockup Expiration
Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.7$198.29-0.2%$8.88 billion$1.45 billion18.76
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.13-0.9%$8.08 billion$40.56 million-15.87
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$155.50-0.7%$8.00 billion$3.34 million-20.19Analyst Upgrade
Analyst Revision
News Coverage
Gap Down
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$73.05-0.3%$7.60 billion$87.99 million-86.96
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$110.29-0.5%$7.44 billion$103.71 million-25.12
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$135.63-2.5%$7.29 billion$14.98 million-16.52Upcoming Earnings
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96-0.0%$6.86 billion$311.33 million-127.30
Perrigo logo
PRGO
Perrigo
2.2$45.46-0.9%$6.07 billion$4.84 billion-757.54Earnings Announcement
Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$75.13-1.2%$5.99 billion$380.83 million-9.61
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$93.88-2.7%$5.48 billion$66.51 million17.32Insider Selling
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$37.32-2.5%$5.26 billion$1.12 billion77.75Analyst Report
Galapagos logo
GLPG
Galapagos
1.3$77.00-1.1%$5.04 billion$1.00 billion-11.67Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$33.85-1.2%$4.79 billion$150,000.00-15.97Earnings Announcement
Analyst Revision
I-Mab logo
IMAB
I-Mab
1.2$63.60-2.0%$4.60 billion$4.31 million-2.20News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$70.27-0.6%$4.57 billionN/A-5.73Analyst Report
Schrödinger logo
SDGR
Schrödinger
1.6$61.45-0.3%$4.30 billion$85.54 million0.00Insider Selling
Analyst Revision
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$53.06-16.6%$4.27 billionN/A-7.15Analyst Report
Unusual Options Activity
News Coverage
Gap Up
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$72.75-2.6%$4.25 billion$6.87 million-7.03
LEGN
Legend Biotech
1.3$30.90-4.2%$4.11 billion$64.39 million0.00Analyst Report
High Trading Volume
News Coverage
Gap Up
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$26.75-3.5%$3.98 billion$204.89 million-33.44
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$60.89-0.9%$3.70 billion$806.43 million-8.62
Alkermes logo
ALKS
Alkermes
1.2$22.08-0.8%$3.54 billion$1.17 billion-48.00
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$70.45-1.6%$3.46 billionN/A-20.07
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$55.72-0.9%$3.43 billion$117.91 million-11.30
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.23-2.5%$3.40 billion$339.08 million-12.34Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.19-4.3%$3.32 billion$114.62 million-7.33Analyst Report
Insider Selling
Arvinas logo
ARVN
Arvinas
1.7$67.24-0.5%$3.29 billion$42.98 million-26.27
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$110.73-2.8%$3.26 billionN/A-55.09
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$60.29-2.8%$3.23 billion$1.11 billion19.39
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$37.10-1.3%$3.01 billion$60,000.00-11.52Analyst Upgrade
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$79.07-0.9%$2.86 billion$26.52 million-6.97
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$73.29-0.9%$2.80 billion$644.77 million-10.46Upcoming Earnings
MorphoSys logo
MOR
MorphoSys
0.3$20.93-0.1%$2.75 billion$80.43 million99.67
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.3$61.60-1.0%$2.71 billion$421.03 million21.69Analyst Report
Insmed logo
INSM
Insmed
1.2$26.04-0.7%$2.69 billion$136.47 million-10.02Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.5$38.00-0.0%$2.68 billion$306.98 million-5.44Analyst Report
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$40.40-1.3%$2.56 billionN/A-22.20Earnings Announcement
Analyst Revision
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.7$21.41-0.8%$2.50 billion$306.49 million24.06
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.